TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04205565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Oxiracetam Injection
Description: Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group: Placebo Injection
Description: Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
Study: NCT02431364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdinexor
Description: Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
Study: NCT04227132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard computerized training
Description: Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
Study: NCT01497249

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A dietary fiber (FCHO)
Description: 15 g twice per day in beverage
Study: NCT01497249

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink
Study: NCT02815423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Transplatation of umbilical cord mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous
Description: Percutaneous injection
Study: NCT03256318

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; surveys/questionnaires only

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; surveys/questionnaires only
Study: NCT02431364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdinexor
Description: Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdinexor
Description: Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
Study: NCT03065192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VY-AADC01
Description: Single dose, neurosurgically infused, bilaterally into the striatum.
Study: NCT02403258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle group
Description: Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HRT group
Description: HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
Study: NCT01433367

Intervention type: DEVICE
Intervention: CerPass® Total Disc Replacement
Description: Single level cervical disc disease
Study: NCT02423421

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faecal microbiota transplantation
Description: Human Stool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Faecal microbiota transplantation
Description: Human Stool.
Study: NCT04402411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: The patient will be placed in a lateral position with the side to be blocked facing upwards. The ultrasound probe will be properly sterilized and with sterile covers. An 18-20 gauge blunt tipped block needle or a Tuohy needle is advanced under ultrasound guidance on the posterior aspect of the Quadratus Lumborum. The QL muscle is identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the QL muscle adherent to the apex of the transverse process, a well recognisable pattern of a shamrock with three leaves can be seen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: The patient will be supine while performing the block and sterilization of the site of the ultrasound and needle entry will be performed.~The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest.~The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles.
Study: NCT02500433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Kinect-Xbox 360TM
Description: Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Study: NCT04274127

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)
Description: completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
Study: NCT04338971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IpsiHand Therapy
Description: The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
Study: NCT04402411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous opioid
Description: Patients will receive morphine 0.1 mg/kg
Study: NCT02245607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational Therapy
Study: NCT02872428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: By infusion over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: By infusion over 1 hour
Study: NCT01436630

Intervention type: OTHER
Intervention: Step Test and Six Minute Walk.
Description: The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
Study: NCT01729949

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment Beverage
Description: Strawberry and Blackcurrent extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment Beverage
Description: without active components
Study: NCT03281018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Accompaniment Time (CAT) + preoperative hypnosis session
Description: The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
Study: NCT02301390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Amiodarone is a Class III antiarrhythmic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone is a Class III antiarrhythmic agent.
Study: NCT03452709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
Study: NCT02301390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
Study: NCT02072980

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel contact lenses
Study: NCT03452709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABPM ambulatory blood pressure monitoring
Description: Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
Study: NCT04511260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuEra Tight VRF Handpiece
Description: The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue.
Study: NCT00708110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it.
Study: NCT03818165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR2 Anti-CEA CAR-T cells
Description: doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
Study: NCT02627586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
Study: NCT00708110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it.
Study: NCT03522766

Intervention type: OTHER
Intervention: urine sample
Description: The subjects are asked to give a maximum of 15 urine samples during the study

Intervention type: OTHER
Intervention: urine sample
Description: The subjects are asked to give a maximum of 15 urine samples during the study
Study: NCT04236739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instant MSC Product accompanying Autologous Chondron Transplantation
Description: Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
Study: NCT01250041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous femoral nerve block
Description: ultrasound guided femoral nerve catheter insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous saphenous nerve block
Description: ultrasound guided saphenous nerve catheter insertion
Study: NCT02818049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage
Description: BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
Study: NCT04371666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab per dose and schedule specified in the arm description
Study: NCT00266630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: oral, daily
Study: NCT01489072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
Study: NCT01907828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Artery Ablation
Description: Renal artery denervation using the EnligHTN™ Renal Denervation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Ablation
Description: Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Ablation
Description: Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
Study: NCT03444974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: adapted treatment according to the MATRIX-A therapy
Description: cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: adapted treatment according to the MATRIX-A therapy
Description: cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
Study: NCT01312584

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Processed High-flavanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Processed High-flavanol
Study: NCT00266630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: Dose adjusted according to local package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate
Description: Dose adjusted according to local package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbamazepine
Description: Dose adjusted according to local package insert
Study: NCT04371666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo per schedule specified in the arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally
Study: NCT04090294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months
Study: NCT01436955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multiple oral doses
Study: NCT03607968

Intervention type: PROCEDURE
Intervention: The novel anterior TVM surgeries
Description: A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
Study: NCT01436955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: Cohorts receiving multiple oral doses
Study: NCT03987997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early association of electrical muscle stimulation with cyclo-ergometer
Description: Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
Study: NCT01312584

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Processed High-flavanol
Study: NCT03987997

Intervention type: DEVICE
Group type: OTHER
Intervention: Early association of electrical muscle stimulation with cyclo-ergometer
Description: Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
Study: NCT02738138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493 coformulated with ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493 coformulated with ABT-530
Description: Tablet
Study: NCT00625820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6R BH4
Description: 400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 500 mg Vitamin C oral BID for another 6 weeks
Study: NCT03290963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium will be dosed in units (LI level \> or = 0.4 milliequivalents (mEq)/L)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, dosed in units
Study: NCT04547452

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Sintilimab Combined with SBRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 antibody drug named Sintilimab
Description: Sintilimab
Study: NCT00928694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate (U.S. formulation)
Description: Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate (UK formulation)
Description: Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
Study: NCT04547452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody drug named Sintilimab
Description: Sintilimab
Study: NCT00486720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
Study: NCT02347345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
Description: Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
Study: NCT03290963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.